Stratification of treatment of postmenopausal osteoporosis;Stratifikace léčby postmenopauzální osteoporózy

Prakticky Lekar

Volumn 84, Issue 9, 2004, Pages 500-506

  Štěpán, Jan ^a   Payer, J ^b   Abrahamova J ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Interná Klinika Odd Paliatívnej Medicíny   (Slovakia)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

Author keywords

Bisphosphonates; Fracture; Osteoporosis; Raloxifene; Teriparatide

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MINERAL; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; SIDE EFFECT; VERTEBRA FRACTURE;

EID: 6344233672     PISSN: 00326739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. Geneva, World Health Organisation, 1994.
2. Barrett Connor, E., Grady, D., Sashegyi, A., et al.: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA, 2002, 287, p. 847-857.
3. Beral, V.: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 2003, 362, p. 419-427.
4. Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., et al.: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys., 2000, 373, p. 231-241.
5. Black, D. M., Arden, N. K., Palermo, L., et al.: Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res., 1999, 14, p. 821-825.
6. Black, D. M., Cummings, S. R., Karpf, D. B., et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 1996, 348, p. 1535-1541.
7. Boivin, G., Chavassieux, P., Meunier, P.: Histomorphometry of bone Effects of different treatments on bone remodeling and mineralization. Osteol. Bull., 2002, 7, p. 5-9.
8. Boivin, G., Meunier, P. J.: Effect ob bisphosphonates on matrix mineralization. J. Musculoskel. Neuron Interact., 2002, 2, p. 538-842.
9. Boivin, G. Y., Chavassieux, P. M., Santora, A. C., et al.: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone, 2000, 27, p. 687-694.
10. Bone, H. G., Hosking, D., Devogelaer, J. P., et al.: Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med., 2004, 350, p. 1189-1199.
11. Bryant, H. U.: Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation. Rev. Endocr. Metab. Disord., 2001, 2, p. 129-138.
12. Cauley, J. A., Norton, L., Lippman, M. E., et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial, Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat., 2001, 65, p. 125-134.
13. Cauley, J. A., Thompson, D. E., Ensrud, K. C., et al.: Risk of mortality following clinical fractures. Osteoporos. Int., 2000, 11, p. 556-561.
14. Cox, D. D., Sarkar, S., Harper, K., Barrett-Connor, E.: Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. Current Med. Res. Opinion, 2004, 20, p. 1049-1055.
15. Cummings, S. R., Black, D. M., Thompson, D. E., et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA, 1998, 280, p. 2077-2082.
16. Cummings, S. R., Nevitt, M. C., Browner, W. S., et al.: Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N. Engl. J. Med., 1995, 332, p. 767-773.
17. Delmas, P. D., Ensrud, K. E., Adachi, J. D., et al.: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab., 2002, 87, p. 3609-3617.
18. Eriksen, E. F., Meisen, F., Sod, E., et al.: Effect of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone, 2002, 31, p. 620-625.
19. Ettinger, B., Black, D. M., Mitlak, B. H., et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 1999, 282, p. 637-645.
20. Ettinger, B., San Martin, J., Crans, G. G., Pavo, I.: Differential effects of teriparatide on BMD dafter treatment with raloxifene or alendronate. J. Bone Miner. Res., 2004, 19, p. 745-751.
21. Finnern, H. W., Sykes, D. P.: The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos. Int., 2003, 14, p. 429-436.
22. Felsenberg, D., Silman, A. J., Lunt, M., et al.: Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J. Bone Miner. Res., 2002, 17, p. 716-724.
23. Harris, S. T., Watts, N. B., Genant, H. K., et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA, 1999, 282, p. 1344-1352.
24. Havelka, S., Kamberská, Z., Bernátová, M.: Incidence osteoporózy v České republice. Osteol. Bull., 1999, 4, s. 2-6.
25. Heaney, R. P., Zizic, T. M., Fogelman, I., et al.: Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos. Int., 2002, 13, p. 501-505.
26. Hui, S. L., Slemenda, C. W., Johnston, C. C., Jr.: Age and bone mass as predictors of fracture in a prospective study. J. Clin. Invest., 1988, 81, p. 1804-1809.
27. Chesnut, C. H., Silverman, S., Andriano, K., et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Amer. J. Med., 2000, 109, p. 267-276.
28. Kanis, J. A., Johnell, O., Black, D. M., et al.: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone, 2003, 33, p. 293-300.
29. Kanis, J. A., Johnell, O., Oden, A., et al.: Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone, 2002. 30, p. 251-258.
30. Kloosterboer, H. J., Ederveen, A. G. H.: Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (± progestogen) treatments. J. Steroid Biochem. Mol. Biol., 2003, 83, p. 157-165.
31. Klotzbuecher, C. M., Ross, P. D., Landsman, P. B., et al.: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J. Bone Miner. Res., 2000, 15, p. 721-739.
32. Lindsay, R., Silverman, S. L., Cooper, C., et al.: Risk of new vertebral fracture in the year following a fracture. JAMA, 2001. 285, p. 320-323.
33. Martino, S., Cauley, J. A., Barrett-Connor, E., et al.: Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: results from the Continuing Outcomes Relevant to Evista (CORE) trial. ASCO; 2004.
34. Mashiba, T., Turner, C. H., Hirano, T., et al.: Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone, 2001, 28, p. 524-531.
35. McClung, M. R., Geusens, P., Miller, P. D., et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med., 2001, 344, p. 333-340.
36. Meunier, P. J., Boivin, G.: Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone, 1997, 21, p. 373-377.
37. Meunier, P. J., Roux, C., Seeman, E., et al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med., 2004, 350, p. 459-468.
38. Meunier, P. J., Sebert, J. L., Reginster, J. Y., et al.: Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FA-VOStudy. Osteoporos. Int., 1998, 8, p. 4-12.
39. Michalska, D., Štěpán, J., Térová, M., et al.: Effect of raloxifene on bone mineral density and markers of bone remodeling following alendronate therapy. Calcif. Tissue Int., 2003, 27, p. 401.
40. Neer, R. M., Arnaud, C. D., Zanchetta, J. R., et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 2001, 344, p. 1434-1441.
41. NIH Consensus Development Panel on osteoporosis prevention, diagnosis, and therapy. JAMA, 2001, 285, p. 785-795.
42. O'Neill, T. W., Felsenberg, D., Varlow, J., et al.: The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J. Bone Miner. Res., 1996, 11, p. 1010-1018.
43. Randeli, K. M., Honkanen, R. J., Kroger, H., Saarikoski, S.: Does hormone-replacement therapy prevent fractures in early postmenopausal women? J. Bone Miner. Res., 2002, 17, p. 528-533.
44. Reginster, J., Minne, H. W., Sorensen, O. H., et al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int., 2000, 11, p. 83-91.
45. Roy, D. K., Pye, S. R., Lunt, M., et al.: Falls explain between-center differences in the incidence of limb fracture across Europe. Bone, 2002, 31, p. 712-717.
46. Rymer, J., Robinson, J., Fogelman, I.: Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric, 2002, 5, p. 389-398.
47. Schaffer, M. B., Choi, K., Milgrom, C.: Aging and matrix microdamage accumulation in human compact bone. Bone, 1995, 17, p. 521-525.
48. Siris, E., Adachi, J. D., Lu, Y., et al.: Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation. Osteoporos. Int., 2002, 13, p. 907-913.
49. Sorensen, O. H., Crawford, G. M., Mulder, H., et al.: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone, 2003, 32, p. 120-126.
50. Štěpán, J., Záhora, R., Polá ková, L., Křenková, J., Mašatová, A.: Prevalence osteoporózy v České republice. Čas. Lék. čes., 1998, 137, s. 237-239.
51. Stěpán, J. J., Havelka, S., Kamberská, Z., Bernátová, M.: Epidemiologie der Osteoporose in der Tschechischen Republik. J. Mineralstoffwechsel, 2002, 9, S. 7-13.
52. Still, K., Phipps, R. J., Scutt, A.: Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro. Calcif. Tissue Int., 2003, 72, p. 145-150.
53. Taranta, A., Brama, M., Teti, A., et al.: The selective estrogen receptor modular raloxifene regulates osteoclast and osteoblast activity in vitro. Bone, 2002, 30, p. 368-376.
54. Tonino, R. P., Meunier, P. J., Emkey, R., et al.: Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab., 2000, 85, p. 3109-3115.
55. Writing Group for the Women'sd Health Initiative: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, p. 321-333.